RSS-Feed abonnieren
DOI: 10.1055/s-0039-1678719
To Maintain or Cease Non–Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations
Publikationsverlauf
Publikationsdatum:
11. Februar 2019 (online)
![](https://www.thieme-connect.de/media/sth/201902/lookinside/thumbnails/10-1055-s-0039-1678719_02601-1.jpg)
Abstract
For procedures associated with minimal bleeding risk, there are data and experience to support the practice of continuing vitamin K antagonists rather than interrupting therapy, to prevent exposing patients to the undue risk of developing thromboembolism during anticoagulation cessation. Despite the increasing use of non–vitamin K oral anticoagulants (NOACs), there is little evidence to guide the management of these drugs around minimal bleeding risk procedures. This review examines and discusses the major society guidelines and recommendations addressing the management of NOACs around minimal bleeding risk procedures. Additionally, it summarizes the existing evidence, and highlights the gaps in knowledge where evidence is not yet available. Finally, recommendations are made to assist the proceduralist deal with this area of limited evidence.
Keywords
Non–vitamin K oral anticoagulants - direct oral anticoagulants - anticoagulation - surgery - minimal bleeding risk - dental procedure - dermatologic surgeryStatement of Limitations
As searches were limited to the PubMed database and the English language, we could not be certain that the search was all inclusive for all guidelines, or all the “minimal bleeding risk procedures” potentially covered, but as the search uncovered guidelines from the major societies, and a range of anticipated “minimal bleeding risk procedures” were covered, we believe the report to reflect a fair representation of the literature.
-
References
- 1 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
- 2 Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017; 12 (06) 589-596
- 3 Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart 2016; 3 (01) e000279
- 4 Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41 (01) 206-232
- 5 Food and Drug Administration. Pradaxa approval letter. 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022512s000ltr.pdf . Accessed August 23, 2018
- 6 Food and Drug Administration. Approval Letter - Andexxa. 2018. Available at: www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm606693.pdf . Accessed August 23, 2018
- 7 Ansell JE, Bakhru SH, Laulicht BE. , et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017; 117 (02) 238-245
- 8 ClinicalTrials.gov. Phase 2 study of apixaban reversal by ciraparantag as measured by WBCT. Available at: https://clinicaltrials.gov/ct2/show/NCT03288454?term=NCT03288454&rank=1 . Accessed August 23, 2018
- 9 Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017; 18 (07) 598-608
- 10 Gosselin RC, Adcock DM, Bates SM. , et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
- 11 Douketis JD, Spyropoulos AC, Anderson JM. , et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost 2017; 117 (12) 2415-2424
- 12 Douketis JD, Spyropoulos AC, Spencer FA. , et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e326S-e350S
- 13 Raval AN, Cigarroa JE, Chung MK. , et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 2017; 135 (10) e604-e633
- 14 Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 2016; 14 (05) 875-885
- 15 Tran H, Joseph J, Young L. , et al; Australasian Society of Thrombosis and Haemostasis. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 2014; 44 (06) 525-536
- 16 Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368 (22) 2113-2124
- 17 Albaladejo P, Bonhomme F, Blais N. , et al; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med 2017; 36 (01) 73-76
- 18 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20: 1231-1242
- 19 Garcia D, Alexander JH, Wallentin L. , et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014; 124 (25) 3692-3698
- 20 Beyer-Westendorf J, Gelbricht V, Förster K. , et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35 (28) 1888-1896
- 21 Healey JS, Eikelboom J, Douketis J. , et al; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126 (03) 343-348
- 22 Shaw JR, Woodfine JD, Douketis J, Schulman S, Carrier M. Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Res Pract Thromb Haemost 2018; 2 (02) 282-290
- 23 Chan FKL, Goh KL, Reddy N. , et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018; 67 (03) 405-417
- 24 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
- 25 Brekelmans MP, Scheres LJ, Bleker SM. , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost 2017; 117 (04) 809-815
- 26 Ferreira M, Barsam S, Patel JP. , et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2016; 173 (02) 314-315
- 27 Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (11) 1674-1683.e3
- 28 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
- 29 Food and Drug Administration. Savaysa NDA approval. 2015. Available at: www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206316Orig2s000ltr.pdf . Accessed August 23, 2018
- 30 Gómez-Moreno G, Fernández-Cejas E, Aguilar-Salvatierra A, de Carlos F, Delgado-Ruiz RA, Calvo-Guirado JL. Dental implant surgery in patients in treatment by dabigatran. Clin Oral Implants Res 2018; 29 (06) 644-648
- 31 Brennan Y, Gu Y, Favoloro EJ. , et al. Dental extractions on NOACs without stopping therapy (DENTST) study: interim analysis. Presented at HAA Annual Scientific Meeting; October 29–November 1, 2017; Sydney, Australia
- 32 Brennan Y, Gu Y, Favoloro EJ. , et al. Dental extractions on NOACs without stopping therapy (DENTST) study: interim analysis. Res Pract Thromb Haemost 2017; 1 (Suppl. 01) 986
- 33 Brennan Y, Gu Y, Favoloro EJ. , et al. Dental extractions on NOACs without stopping therapy (DENTST) study: interim analysis. Presented at the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis; October 6–9, 2016; Taipei, Taiwan
- 34 Chang TW, Arpey CJ, Baum CL. , et al. Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. Dermatol Surg 2015; 41 (07) 784-793
- 35 Heard LK, Shanahan C, Maggio KL. Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. Dermatol Surg 2017; 43 (04) 597-599
- 36 Cheung JJC, Liu S, Li KKW. Phacoemulsification cataract surgery in patients receiving novel oral anticoagulant medications. Int Ophthalmol 2018 Doi: 10.1007/s10792-018-0862-x
- 37 Heublein V, Pannach S, Daschkow K, Tittl L, Beyer-Westendorf J. Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. J Gastroenterol 2018; 53 (02) 236-246
- 38 Westerman ME, Scales JA, Sharma V, Gearman DJ, Ingimarsson JP, Krambeck AE. The effect of anticoagulation on bleeding-related complications following ureteroscopy. Urology 2017; 100: 45-52
- 39 Culkin DJ, Exaire EJ, Green D. , et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014; 192 (04) 1026-1034
- 40 Douketis JD, Berger PB, Dunn AS. , et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 299S-339S
- 41 Yui JC, Preskill C, Greenlund LS. Arthrocentesis and joint injection in patients receiving direct oral anticoagulants. Mayo Clin Proc 2017; 92 (08) 1223-1226
- 42 Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol 2015; 187: 426-429
- 43 Calkins H, Hindricks G, Cappato R. , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm 2017; 33 (05) 369-409
- 44 Cappato R, Marchlinski FE, Hohnloser SH. , et al; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36 (28) 1805-1811
- 45 Calkins H, Nordaby M. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017; 377 (05) 495-496
- 46 Kirchhof P, Haeusler KG, Blank B. , et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 2018; 39 (32) 2942-2955
- 47 Brieger D, Amerena J, Attia J. , et al; NHFA CSANZ Atrial Fibrillation Guideline Working Group. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ 2018; 27 (10) 1209-1266
- 48 Birnie DH, Healey JS, Wells GA. , et al; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368 (22) 2084-2093
- 49 Kumbhani DJ. A randomised controlled trial of continued versus interrupted direct oral anti-coagulant at the time of device surgery - BRUISE CONTROL-2. 2017. Available at: http://www.acc.org/latest-in-cardiology/clinical-trials/2017/11/10/21/56/bruise-control-2 . Accessed April 23, 2018
- 50 Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother 2006; 40 (12) 2205-2210
- 51 American Dental Association. Anticoagulant and antiplatelet medications and dental procedures. 2015. Available at: https://www.ada.org/en/member-center/oral-health-topics/anticoagulant-antiplatelet-medications-and-dental-#.WqTDI3N4ZdI . Accessed August 23, 2018
- 52 Scottish Dental Clinical Effectiveness Programme. Management of dental patients taking anticoagulants or antiplatelet drugs: dental clinical guidance. Available at: http://www.sdcep.org.uk/published-guidance/anticoagulants-and-antiplatelets . Accessed August 23, 2018
- 53 Acosta RD, Abraham NS, Chandrasekhara V. , et al; ASGE Standards of Practice Committee. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83 (01) 3-16
- 54 Veitch AM, Vanbiervliet G, Gershlick AH. , et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2016; 48 (04) c1
- 55 FSRH Clinical Effectiveness Unit. CEU statement: management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants. 2017. Available at: www.fsrh.org/news/new-guidance-on-management-of-anticoagulants-or-antiplatelet . Accessed April 8, 2018
- 56 Patel IJ, Davidson JC, Nikolic B. , et al; Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement; Standards of Practice Committee of the Society of Interventional Radiology. Addendum of newer anticoagulants to the SIR consensus guideline. J Vasc Interv Radiol 2013; 24 (05) 641-645
- 57 Yagyuu T, Kawakami M, Ueyama Y. , et al. Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin: a retrospective cohort study. BMJ Open 2017; 7 (08) e015952
- 58 Patel JP, Woolcombe SA, Patel RK. , et al. Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery. Br Dent J 2017; 222 (04) 245-249
- 59 Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122 (05) e146-e155
- 60 Morimoto Y, Yokoe C, Imai Y, Sugihara M, Futatsuki T. Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants. J Dent Sci 2016; 11: 59-64
- 61 Gómez-Moreno G, Aguilar-Salvatierra A, Fernández-Cejas E, Delgado-Ruiz RA, Markovic A, Calvo-Guirado JL. Dental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban. Clin Oral Implants Res 2016; 27 (06) 730-733
- 62 Clemm R, Neukam FW, Rusche B, Bauersachs A, Musazada S, Schmitt CM. Management of anticoagulated patients in implant therapy: a clinical comparative study. Clin Oral Implants Res 2016; 27 (10) 1274-1282